A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: MK0731

Study type: Interventional

Funder types: Industry

Identifiers

NCT00104364

2005_004

0731-002

Details and patient eligibility

About

The purpose of this trial is to study MK0731 in patients with recurrent or non-responsive solid tumors, or cancers for which standard therapy does not exist.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are at least 18 years of age with recurrent or non-responsive solid tumors, or cancers for whom standard therapy does not exist. Part of the study includes only patients who have taxane-resistant cancers.

Exclusion criteria

• Patients who have had treatment with any investigational therapy within the past 30 days.
• Patients who have certain types of blood cancers such as leukemia or lymphoma.
• Patients who have uncontrolled congestive heart failure (CHF), chest pains, or had a heart attack within the past 3 months, or have undergone bone marrow or stem cell transplantation.
• Patient is pregnant or nursing.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)